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INTRODUCTION 
  Chronic obstructive pulmonary disease, one of  common treatable 
& preventable entity, with limitation of  airflow that is persistant, 
progressive and is  associated with increased inflammatory response in 
the lungs and airways to the noxious gases or particles. The previous 
terms like emphysema, chronic bronchitis are not used nowadays. 
                It is one of a common cause of morbidity and mortality 
globally, that leads to financial and social burden. According to one 
estimate, its prevalence is around 9-10 % and  it is the third leading cause 
of death globally. In India its prevalence varies, and it accounts for 
almost 5,00,000 deaths per year. 
              Tobacco smoking and smoke from biomass, occupational 
exposure to noxious gas or particles, passive smoking, alpha-1 anti 
trypsin deficiency are the commonly implicated risk factors for the 
development of this disease. 
COPD is diagnosed by risk factors exposure history, clinical 
examination, airflow limitation is assessed by post bronchodilator 
spirometry assessment. 
          COPD is not only a respiratory disease, it is a systemic disease 
with many extra pulmonary manifestations. It causes muscle weakness, 
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metabolic diseases like diabetes mellitus, bone diseases like osteopenia, 
osteoporosis, several electrolyte abnormalities, increased risk for 
atherosclerosis, cardiovascular morbidities and mortalities. 
Among electrolyte abnormalities low serum sodium levels and 
potassium levels are more commonly encountered. Low serum sodium 
level may results in cns manifestations, and low serum potassium levels 
manifests as muscle weakness and cardiac conduction abnormalities. 
These electrolyte abnormalities results from the disease process itself or 
due to the medications used. 
           So careful search of these electrolyte abnormalities and 
appropriate intervention is important in COPD patients. 
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AIMS AND OBJECTIVES 
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AIMS AND OBJECTIVES 
 
 
 
1. To measure serum electrolytes in chronic obstructive pulmonary 
disease patients. 
 
2. Estimation of prevalence of electrolyte abnormalities in patients 
with chronic obstructive pulmonary disease. 
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REVIEW OF LITERATURE
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ANATOMY OF THE AIRWAYS 
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           CHRONIC  OBSTRUCTIVE  PULMONARY DISEASE 
Chronic obstructive pulmonary disease was defined as a disease  
characterized by the presence of airflow obstruction due to chronic 
bronchitis and emphysema, the airflow obstruction is generally 
progressive and may be accompanied by airway hyper reactivity and may 
be partially reversible. 
          But, according to GOLD/ATS/ERS, COPD, defined as one of a 
common preventable & treatable disease, characterized by limitation of 
airflow, which is not fully reversible. Airflow obstruction is both 
progressive and associated with an abnormal inflammatory response of 
the lungs and airways to the noxious gas and particles. The terms chronic 
bronchitis and Emphysema are no longer used for the definition. 
COPD is not confined the lungs but systemic inflammatory 
involvement are also present. Many extra pulmonary manifestations of 
COPD occurs. These are weakness of muscles, ↑ed  risk of atherosclerotic 
cardiac disease, depressed mental state,↓ed bone density, and altered fluid 
& electrolytes levels, cognitive impairement. 
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EPIDEMIOLOGY OF COPD 
DISEASE BURDEN 
Worldwide COPD has emerged as a major cause of morbidity and 
mortality which causes financial and social burden that is both substantial 
and increasing1 and According to the Global Burden Of Disease Study 
(GBDS) projection, COPD will be the third most common cause of  
mortality. COPD, twelfth leading cause of DALYs lost globally, around 
1990.and now projected that this disease will be the seventh leading 
cause of loss of Disability Adjusted Life Years (DALY)  in 20301.COPD 
burden is cumulative and keeps on adding with time. however the losses 
from DALY and premature mortality are reduced with improvement in 
the treatment for COPD. 
GLOBAL PREVALENCE 
              Prevalence of COPD in adult population more than forty years 
of age is 9-10 percent approximately worldwide2..COPD  causes more 
than 3 million deaths per year globally making it the third leading cause 
of death worldwide3. 
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INDIAN SCENARIO 
              To know the prevalence of COPD in India ,a study was carried 
by Wig et al in 1964 in Delhi. In that study,3.36 % and 2.54% prevalence 
was present in males, females respectively4.In India, chronic respiratory 
diseases (CRDs) account for 3% of DALYs, and COPD is the major 
cause among CRDs 5. In India, this disease causes about 500,000 deaths 
per year.6 
            Indian Study on Epidemiology of Asthma, Respiratory symptoms, 
and Chronic Bronchitis in adults (INSEARECH) study was conducted in 
the recent time7.It showed that in India prevalence of  chronic Bronchitis 
in adults aged more than 35 years is 3.49 percent, varied  from place to 
place (Mumbai 1.1%, thiruvananthapuram 10%). This indicates that, in 
india, there are different prevalence rate. 
RISK FACTORS FOR COPD DEVELOPMENT 
             Multiple risk factors are involved in the disease development. 
They are divided into environmental related factors & host related 
factors. 
           Tobacco smoking and alpha-1 anti trypsin deficiency are the two 
well known documented risk factors for disease development. But the 
specific mechanisms for the development of COPD in these condition 
remains to be determined. 
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          Eventhough smoking of tobacco is the most important one for 
COPD, presence of COPD in non smokers indicates that there are others 
factors also present8.Alpha-1 antitrypsin deficiency accounts for 1-2 % 
COPD 9 
        
 
 
ENVIRONMENTAL  FACTORS 
SMOKING 
80 to 90 percent of COPD in united States is caused by tobacco 
smoking. globally the most common risk factor is cigarette smoking. 
Decreased ventillatory capacity is more common in them. Lung Health 
Study found, in smokers of middle age with an FEV1 of 55-90 %,two 
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hundred ml in FEV1difference is noted  in 5 years between the persons 
who stopped smoking and those not stopped. This difference between 
those continue to smoke and those stopped smoking is doubled over the 
next 6 years. 
Other types of smoking like cigar, pipe, waterpipe, marijuana are 
also risk factors for the development 10,11.passive smoking also called as 
environmental tobacco smoke also increases the risk by increasing the 
load of inhaled particles and gases. Filtered cigarettes or low tar products 
are as harmful as regular cigarettes as like bidi, which may be more 
harmful also. 
If mother smokes during pregnancy, it increases the risk to the 
foetus, by negatively impacting development of the lungs by immune 
system priming in utero11. 
 
OCCUPATIONAL  EXPOSURE 
It includes 
1. organic and inorganic dusts 
2. fumes and chemical agents. 
3. Animal dung,crop residues 
4. wood and coal that is burnt in open fires 
5. Biomass cooking and heating in less well ventilated dwellings.12-21 
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SOCIOECONOMIC STATUS 
              There is inverse correlation between the disease development 
and the socioeconomic status. That is it is more common among low 
socioeconomic people. 
INFECTION 
             Susceptibility to infection causes exacerbation of COPD, but its 
role in the development of the disease is less clear. Human Immune 
Deficiency Virus infection increases the smoking related emphysema risk 
22Tuberculosis23 is also considered, but its role is less clear. 
LUNG GROWTH AND DEVELOPMENT 
Any factors which affects lung growth and development during 
intra uterine or during childhood increases the risk. A study found that 
childhood factors were also important to assess lung function in adult 
life. 
GENETIC FACTOR 
ALPHA-1 ANTI-TRYPSIN DEFICIENCY 
The best documented genetic risk factor is the hereditary 
deficiency of Alpha-1 anti trypsin, which is a major circulating serine 
protease inhibitor. Alpha -1 anti trypsin synthesis occurs in liver. Normal 
alpha1 antitrypsin is by M allele. Severe form of alpha1-antitrypsin 
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deficiency caused by the SERPINA 1 gene mutation, present on the long 
arm of chromosome 14 and it causes the Z allele24. one study shows that 
α1-antitrypsin deficiency seen in 1-2 per cent in COPD. Gene that 
encodes matrix metalloproteinase 12 ( MMP-12 ) is also associated with 
reduced lung function and COPD25. MMP-12 polymorphism is an 
protective factor for COPD26. 
 
 
                The above table shows the conditions associated with alpha -1 
anti trypsin deficiency associated respiratory diseases 
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PATHOLOGY 
                  Tobacco smoke contains approximately 6,000 chemicals, 
contain highly reactive oxidant species. Smokes from cigarette, biomass 
fuels, and others cause, a normal inflammation response, in COPD it is 
altered. This causes destruction of lung parenchyma, leading to 
emphysema and also resulting in small airway fibrosis because of 
disruption of normal mechanisms of defence. These changes leads to 
trapping of air & airflow limitation. These pathological changes are 
present in the lung parenchyma and pulmonary vasculature. These 
structural and inflammatory airway changes  increases with disease 
severity and persists on cessation of smoking. Exact mechanism is 
unknown, autoantigens and persistant micro organism may contribute for 
this. But if an individual stops smoking in the early phase, these changes 
may be reversible. 
 
PATHOGENESIS 
In COPD patients, the respiratory tract inflammation is a modified 
inflammatory response of the respiratory tract to chronic irritation like 
cigarette smoking. Mechanism for this increased inflammatory is less 
known, genetic factors play a role for this development. Non smokers 
also can develop COPD, but the inflammatory response is notknown. 
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Oxidant stress and an increased level of lung proteinases also changes the 
inflammation.  
 OXIDATIVE STRESS 
Oxidative stress biomarkers are increased in expired breath, 
systemic circulation, sputum of the patients. It is increased during 
exacerbation. Cigarette smoke and other particle inhalation produce 
oxidants, the inflammatory cells like macrophages & neutrophils releases 
these. As a result of decreased levels of transcription factor(Nrf-2) which 
regulates anti oxidant genetic componant, causes reduction in the level of 
endogenous antioxidants. Inactivation of cofactor HDAC2  
(histone diacetylase 2) play a vital role. It is a cofactor for down 
regulation of  proinflammatory genes by glucocorticoids. 
PROTEASE-ANTI PROTEASE IMBALANCE 
There is an imbalance in the lungs of COPD patients between 
proteases which breaks connective tissue component & anti-proteases 
which prevents/protects against the break down. Epithelial cells and 
inflammatory cells derived proteases are increased in COPD patients, 
these proteases interact with each other. A connective tissue component 
of the parenchyma of the lung, Elastin, which is destroyed by protease, is 
a feature of Emphysema, and is mostly not irreversible. 
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INFLAMMATORY CELLS 
Macrophages got accumulated in the airways. Mediators  from 
these Macrophages are an  important pathogenic mediators. Within 
airways, airway glands neutrophils are present and accumulates.27-31  
           Lymphocytes especially CD8+ lymphocytes are also present in the 
airways. increased number of CD8+ cells are associated with more severe 
disease32-37.mast cells are also ↑ed in COPD and mediators of  mast cell 
are present in bronchoalveolar lavage fluid in COPD patients38. 
Eosinophil derived mediators are also present 39-42, these patients may 
respond to glucocorticoids43.Studies reveals that the inflammatory 
process persists if the disease advances to a certain point. 
INFLAMMATORY MEDIATORS 
There are wide variety of inflammatory mediators are present in 
COPD. Inflammatory cells from the circulation are attracted by these 
inflammatory mediators, inflammation is increased by proinflammatory 
cytokines, growth factors induces the structural changes. 
Many have documented increase in neutrophil chemotactic factors 
levels in COPD patients.According to one study, the following factors are 
found in sputum44-48. 
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1. Tumor necrosis factor (TNF)  
2. Interleukin-8 (IL-8) 
3. C-X-C ligand 1 (CXCL 1) 
4. monocyte chemoattractant protein (MCP)-1  
 
Recently It is shown that  increased levels of cytokines are present 
over time in COPD. Increased chemokines , chemotactic factors and 
chemotactic receptors are also found in bronchoalveolar lavage & lung 
tissue. 
 
INFLAMMATORY PATHWAYS 
Cyclic nucleotides act as a common signaling pathway.Chemotaxis 
of neutrophil is modified by cyclic nucleotides. Cyclic guanosine 
monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP)49-
50
  are the two cyclic nucleotides commonly involved. 
Increased cAMP decreases adhesion and migration of leukocytes. 
C-AMP mediated mechanisms is an important mechanism for 
theophylline effect in COPD. PDE-4 (Phosphodiesterase-4) inhibitors 
have antiinflammatory effect by increasing cAMP levels51. 
A new concept is that  injury to the lung and remodelling of airways 
is by cytokines.NF-kappa B modifies IL-8, granulocyte-macrophage-
colony stimulating factor (GMCSF), and RANTES expression52. In 
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airways, these inflammatory cells presence  point out that pro 
inflammatory cytokines are  actively present and causes chemotaxis. 
 
SYSTEMIC EFFECTS 
COPD is not only a disease of respiratory tract,it is an systemic 
inflammatory condition  with systemic effects53.Frequently these 
systemic effects are the common clinical presentation  in these these 
patients. These are 
1. generalized weakness54 
2. cardiovascular disorders (chronic heart failure and coronary artery 
disease, hypertension)55 
3. metabolic diseases (diabetes mellitus,obesity and metabolic 
syndrome), 
4. bone disease (osteopenia  and osteoporosis)56-57 
5. stroke 
6. lung cancer 
7. skeletal muscle weakness 
8. cachexia 
9. anaemia 
10. depression and cognitive impairement. 
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            Infact the most common cause of death in these patients, is 
cardiovascular disease and it is same both milder grade and severe grade 
of the disease. COPD risk at all the levels of disease. Though less well 
defined, systemic manifestations of COPD is caused by cytokines in the 
circulation, which are produced by the lungs. Depression in often seen in 
COPD patients, it might be due to these cytokines which affects mood 
and causes depression. Similarly, ↓ed density of the bone is also 
common, which is also mediated by the cytokines. One literature shows 
that reduction in FEV1 increases the cardiovascular mortality risk by two 
fold, irrespective of age, gender and smoking. One study shows that 
FEV1 reduction of 10 % is associated with 28 percent increase in 
cardiovascular problems. 
 
PATHO PHYSIOLOGY 
 The following pathophysiological changes occur 
1) Limitation in airflow & trapping of air 
2) Abnormalities in exchange of gases 
3) Increased secretion of mucus 
4) Pulmonary vascular Hypertension 
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CLINICAL PRESENTATION 
1.Cough Chronic duration cough which is present daily or intermittently, 
often present in all times of the day,sometimes only at night time. 
2.Chronic sputum production in COPD sputum production is persistant 
3.Acute bronchitis –repeated acute bronchitis can cause COPD. 
4.Difficulty in breathing –dyspnoea is progressive with poor exercise 
tolerance and respiratory tract infection worsens the dyspnoea. 
             COPD is diagnosed by history of exposure to the offending 
particles with above mentioned clinical presentations and the lung 
function tests.<0.7 of post bronchodilator  fev1/fvc suggests persistent 
limitation of airflow and thus COPD, and by using FEV1,chronic 
obstructive pulmonary disease is classified as a)mild, b)moderate, 
c)severe, d)very severe disease. Spirometry is used for the confirmation. 
If not available, clinical symptoms stated above along with increased 
FET (forced expiratory time) can be used, but less useful. A low 
peakflow, though consistent with COPD has poor specificity. 
The exacerbation  is diagosed by sudden change in symptoms, that 
is not related to normal changes which occurs everyday. Severity 
exacerbation Assessment  is done by pulse oxymeter assesement  
(to decide oxygen therapy), ABG (arterial blood gas),acid-base status,  
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X-ray of the chest to exclude other causes, ECG  to find out cardiac 
conditions, complete blood count to find out increased or decreased 
haemoglobin levels, increased WBC count. 
USEFUL CLINICAL SIGNS FOR THE DIAGNOSIS OF COPD 
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ASSESEMENT OF COPD 
 
The main goals are to finding out the severity, Its effect on patient 
health, exacerbations, admission in the hospitals, mortality of the patient, 
to help to choose the treatment modality for the patient. The following 
aspects are considered in the assessement. 
A.Clinical features 
B.Degree of airflow limitation 
C.Risk of exacerbations 
D.Co morbidities 
 
Symptom assessement 
COPD is assessed symptomatically by COPD assessement test 
(CAT), Clinical COPD Questionnaire (CCQ). 
Degree of airflow limitation 
Degree of airflow limitation is assessed by using spirometry, post 
broncho dilator FEV1 and FEV1/FVC is used58. Classification of  the 
patients are based on severity of limitation of flow of air according to 
FEV1 after bronchodilator use.a)GOLD1( MILD)- FEV1> 80%Predicted   
b)GOLD2-MODERATE  ≤ 50% FEV1  <80% Predicted c)GOLD3-
SEVERE ≤ 30 % FEV1<50%  Predicted  d)GOLD4-VERY SEVERE              
FEV1 ≤ 30% Predicted. 
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OTHER  INVESTIGATIONS 
The following investigations are done for COPD patients 
A) X-ray Chest – Less useful to make the diagnosis,but,helpful to 
rule out differential diagnosis like pulmonary tuberculosis 59-62 
B) High resolution CT scan of Thorax – Demonstrate 
hyperinflation and emphysematous bullae63,64. 
C) Pulmonary Function Test – Helpful in excluding chronic 
asthma. lungs diffusion capacity is assessed and is useful to diagnose 
emphysema. 
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D) Arterial Blood Gas Analysis – It is always done if patients is 
having FEV1 < 40% and clinical features of respiratory failure or right 
heart failure is present. PaO2 < 60 Mm of mercury with presence/absence 
of PaCO2 > 45 mmHg with breathing of atmospheric air indicates failure 
of respiration. cyanosis may be present along with this. 
E) Electrocardiography –Done to exclude cardiac causes. 
F) 2Dimensional Echocardiography –Done to find out 
pulmonary hypertension and cardiac failure. 
G) Deficiency of Alpha-1 anti-trypsin – Done  in patients with 
<45 years of age with strong family history and lower lobe emphysema 
H) Six minutes walk test—to monitor exercise capacity in COPD 
patients 
I) SPUTUM EXAMINATION—Is routinely done in india to rule 
out pulmonary tuberculosis65-67 
J) SERUM BIOCHEMICAL ANALYSIS-To find out electrolyte 
abnormalities. 
K) COMPLETE BLOOD COUNT—To find out anemia, 
polychythemia, leukocytosis. 
 
EXACERBATIONS RISK ASSESSEMENT 
Sudden change or worsening in patients symptoms that is beyond 
everyday variations that leading on to need of change of therapy or 
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medication is called as exacerbation of COPD. If the airflow limitations 
worsens, then the risk of exacerbations are also increased. If the COPD  
exacerbation needs hospitalisation, it is associated with bad prognosis 
and increased risk for mortality. If two or more exacerbations are present 
in a year, these type of patients are called as frequent exacerbators. 
 
ASSESSMENT OF SEVERITY OF EXACERBATION* 
These are all indications for admission in to the hospital. The final 
decision depends upon the decision of the treating physician after 
complete assessment.  
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DIFFERENTIAL DIAGNOSES FOR COPD 
A)ASTHMA 
1. Onset is in early age 
2. Symptoms  are episodic.patients are asymptomatic between the 
episodes 
3. Symptoms vary widely day-to-day 
4. Worsening of symptoms during night and early morning 
5. Chronic cough with sputum production is less common 
6. Atopy history may be present 
7. History of asthma in the family may present 
8. Airway obstruction is reversible 
9. 9.↑ DLCO (diffusion capacity of the lung) 
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B) Congestive Heart Failure 
1. Presence of pulmonary edema features and enlarged heart in chest 
X ray 
2. Restrictive pattern pulmonary function test 
 
C) Bronchiectasis 
1. large amount of sputum production 
2. presence of coarse creps 
3. Dilatation of bronchus can be seen in HRCT 
 
D) Tuberculosis 
1. Fever with evening rise of temperature,loss of weight 
2. X-ray chest may show lung opacity, fibrosis or cavitary disease 
3. Diagnosis by microbiological method 
 
E) Constrictive Bronchiolitis 
1. mostly seen in young age persons and non smokers 
2. Transplantation of lung or bone marrow history and rheumatoid 
arthritis may be present 
3. Mosaic pattern in high resolution CT 
 
F) Diffuse Panbronchiolitis 
1. seen in non smokers 
2. Sinusitis may be associated 
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3. Nodules around lobules, air trapping seen in High Resolution CT 
scan. 
MANAGEMENT OF COPD 
Principles in the management of COPD 
1. Cessation of Cigarette smoking 
2. Indoor and outdoor air pollution control 
3. Symptom relief 
4. Exercise tolerance improvement 
5. Treatment and prevention of  complications 
6. Disease progression  prevention 
7. Exacerbations prevention and treatment 
8. Mortality reduction 
9. Preventing or reducing the adverse effects of medications used. 
 
PLAN IN THE MANAGEMENT OF  COPD 
1. Evaluation and monitoring 
2. Risk factors  assessement 
3. Treatment of stable patients and  acute exacerbation patients 
4. Hospitalisation 
 
MONITORING AND EVALUATION 
Detailed clinical, family, exacerbation and past history and 
comorbid illness are recorded and evaluated. 
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RISK FACTOR ADDRESSAL 
Tobacco smoking cessation is the best and cost effective method to 
reduce the COPD risk. Outdoor and indoor air pollution control and 
avoidance is adviced. The patients are advised to avoid heavy outdoor 
exercise, avoid over crowding, ill ventilation, congestion, furniture 
stuffings indoor. 
STABLE COPD-TREATMENT 
When COPD is diagnosed, the treatment is based on analysis of  
individual patients present symptoms and further risk. All the patients 
should be treated with less adverse effects  from therapy, a difficult task  
in  these patients because of presence of associated illness, these also 
should be addressed carefully. 
Two modalities of treatment are used. 
 
A.PHARMACOTHERAPY is used for improvement in 
symptoms, also preventing the future exacerbation, and to improve 
exercise capacity. The following pharmacotherapeutic agents are used 
1) Bronchodilators           2) Glucocorticoids          3)Vaccines 
4) Mucolytic agents          5) Antibiotics                6) Anti-tussives 
7) Respiratory stimulant 
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B.NON-PHARMACOTHERAPY includes pulmonary rehabilitation, 
long term oxygen therapy, surgical interventions 
A) PHARMACOTHERAPY 
STABLE COPD ROUTINELY USED DRUGS AND ITS DOSAGE 
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USE OF BRONCHODILATORS-RECOMMENDATIONS 
a)  Drugs with longer duration of action are preferred over drugs with 
short duration acting for both antimuscaranic and β2 agonist agents 
b)  If  one drug  alone doesnot improve the symptom, combination of  
long or short  acting β2 agonist & anti cholinergics is used. 
c)  Among bronchodilators inhaled route is preferred than oral route. 
d)  Theophyline is advised only in the setting of unavailability of long 
term treatment bronchodilators. 
e)  Antimuscarinic  drugs with longer duration of action are better 
than  longer acting β2 agonists. 
f)  single drug use with Inhaled corticosteroids alone is to be avoided. 
g)  Beta-agonists with short duration of action and short duration 
acting antimuscarinic agents are efficactive equally. 
 
RECOMMENDATIONS REGARDING USE OF MUSCARANIC 
AGENTS  68-70 
a).  Short duration acting antimuscaranic agent (SAMA) are used to 
improve patient symptoms. 
b) Regular use of short acting antimuscaranics are not advised. 
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c). For symptom control and prevention of exacerbation long acting 
drugs are used 
d). Long acting drugs are preferred than short acting drugs. 
e). Coronary artery disease patients should be monitored carefully 
while treating with long acting drugs. 
RECOMMENDATIONS REGARDING USE OF β2 AGONIST71,72  
a)  Short duration acting drugs are used for dyspnoea symptom 
improvement. 
b)  Regular use of long term short acting agent alone in not advised. 
c)  Symptoms are getting relieved and exacerbation frequency is 
decreased when treated with long acting agents monotherapy. 
d) Coronary artery disease patients should carefully monitored when 
inhaled therapy is used. 
 
COTICO-STEROIDS & PDE-4 INHIBITORS USE 73-79  
a)  Short term oral corticosteroide is not recommended. 
b. Long term inhaled steroids are used to treat higher severity of the 
patients when long acting bronchodilating agents are not effective 
c). Long term sterods both oral route and inhalational route is not 
advised. 
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d)  Phosphodiesterase-4 inhibitors therapy may also be used in severe, 
very severe and frequent exacerbation patients,who are not 
adequately controlled by long acting bronchodilators. 
RECOMMENDATIONS REGARDING USE OF COMBINATION 
THERAPY 
a)  Long acting beta agonist and  antimuscaranic agents are used in 
those who didnot get improvement with single drug. 
b)  Inhaled steroids and beta agonist  with long duration of action is 
better than long acting β agonist in those FEV1 <50% or who have 
frequent exacerbations. 
c). For severe degree of disease combination of 3 drugs can be used. 
d) Use of inhaled steroids with either β agonist or anti muscaranics 
are not preferred.  
 
MUCOLYTICS80-82 
                Based on bronchitis randomised on Nac-cost utility study and a 
metaanalysis study, regular use of mucolytics are not recommended. 
VACCINES83-86 
Both pneumococcal  vaccine and Influenza vaccines are available. 
Influenza vaccines reduce severity & death by upto 50%.It is given 
yearly once. But pneumococcal vaccine is given five years once. 
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ANTI-TUSSIVES: In stable patients routine use is better avoided, and is 
contraindicated. 
ANTIBIOTICS: They are during exacerbation 
RESPIRATORY STIMULANTS: routine use is not advised, regardless 
of type. 
B) NON-PHARMACOTHERAPY 
1) PULMONARY REHABILITATION92-95 
2) LTOT(long term o2 therapy)96-98: 
Fifteen hours a day of oxygen is administered.It decreases 
pulmonary vascular resistance,improves exercise capacity and mental 
well being. 
3) Surgery 99-101  
a) Bullectomy: In some it improves dyspnea and respiratory functions. 
b) LVRS (lung volume reduction surgery): 
Upper lobe emphysematous individuals benefitted more. 
                          
MANAGEMENT OF EXACERBATION 
Recommendations 
Patients managed in out patient settings will require no test than 
pulse oxymeter, those who got admitted should be investigated 
completely. sputum examination is done if exacerbation is not controlled 
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by antibiotics. Elderly patients, those who are in shock, altered mental 
status have poor outcome. 
Two components of therapeutic options are available 
(pharmacological & nonpharmacological components).Drugs which 
dilates bronchial tree, corticosteroids & antibiotic agents are used as 
pharmacological means.O2 therapy, ventillatory supports are non 
pharmacological means of treatment options. 
 
PHARMACOLOGICAL TREATMENT 
1st line of drug treatment is with β agonist especially with short 
acting one, anticholinergic drugs may be added. 
Recommendations 
a) Inhalational bronchodilators are preferred. 
b) Inhaled beta agonists are the preferred 1st line drugs as it has 
immediate onset of action. 
c).Salbutamol nebulisation is given q20 minutes for an hour. 
d) Once in 4-6 hours,salbutamol or ipratropium nebulisation can be 
used if not improved. 
e).Meterd dose inhaler or nebulisers are equally effective. 
f).O2 should be given separately through nasal canula,not with 
nebuliser. 
g) Regular use of  IV methylxanthines is better avoided. 
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 RECOMMENDATIONS REGARDING CORTICOSTEROID USE 
          Systemic steroids shorten recovery time, improve lung function, 
oxygenation, reduce length of hospital stay, and/are associated with 
fewer treatment failures. 
a.Prednisolone by oral route is given for short time. 
b.Five to ten days is the duration for systemic steroid 
administration. 
c.Mechanically ventilated patients are given intravenous route. 
d. Regular use of inhaled steroids are not recommended. 
 
RECOMMENDATIONS REGARDING ANTIBIOTIC USE 
a).Given for all patients. 
b).Choosen according to sensitivity. 
c) Quinolones are not used regularly. 
d).1st line antibiotics are used for outpatients. 
e).2nd line are used for in patients and mechanically ventilated 
patients. 
f) Given for 5-7 days. 
RECOMMENDATIONS REGARDING OXYGEN USE 
a).Given for hypoxaemic patients,SpO2 target is 88%-92% . 
b) Given by Venturimask & by nasal O2 during recovery. 
c) ABG monitoring is advised. 
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MECHANICAL VENTILATION-NON-INVASIVE 102-105 
Acute respiratory failure can be treated effectively. It decreases the 
invasive procedure like intubation. 
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             INVASIVE MECHANICAL VENTILATION106,107  
 
 
Treatment of comorbidities Treated as by non-COPD patients. 
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SERUM ELECTROLYTES 
Molecules which gets dissociation in water into their anions & 
cations are electrolytes. they are not again reassemble in the water, 
because of H2o molecules net ionic charge. There are many 
physiologically important molecules, these important molecules are 
sodium, potassium, calcium, magnesium, chloride and bicarbonate. They 
are uniformly present in the body fluids. 
 
Body water compartments are divided into intracellular & 
extracellualar compartments.Interstitial and intra-vascular compartmets 
constitutes extracellular fluid. 
Sodium, the major extra cellular cation, is primarily distributed in 
the extra cellular compartment than intra cellular compartment.Sodium 
entry into the cells is tightly regulated. Entry of sodium into the cells 
cause depolarisation of the cells, which produces action potential. Then 
the sodium is driven out of the cells by 3Na+/2K+ adenosine 
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triphosphatase pump. This pump hydrolyses of Adenosine triphosphate 
into adenosine diphosphate and drives 3 sodium out of the cell and drives 
in 2 potassium at the expense of one ATP. This pump is found in all cells  
in our body. It is the major energy spending process in our body, energy 
spending by the cells by this pump alone is around twenty four 
(24)percent,it is almost seventy (70) percent in neurons. Normal level of 
serum sodium is 136-146 Meq/L. 
Presence of osmotic particles in the extra cellular fluid determines 
extracellular fluid volume. sodium and chloride are the two major 
particles present in the extracellular fluid, chloride levels are mainly get 
altered in response to sodium levels, so sodium ion load is the major 
contributing factor for extra-cellular fluid volume. 
 Potassium is a major intracellular cation. it is maximally 
distributed inside the cells than outside. potassium is the ion which 
maintains the resting membarane potential of the cells. Entry of sodium 
inside the cells cause depolarisation, then the potassium ions move out of 
the cells cause repolarisation, then the potassium is again pumped into 
the cells by the action of sodium, potassium ATPase pump. potassium 
ion level is tightly regulated in the body. kidneys play an important role 
in potassium ion level regulation. normal serum potassium level is  
3.5-5.0 Meq/L. 
43 
 
Calcium regulates proliferation, act as regulator in neuronal 
signalling & learning, muscle contraction and fertilization, so 
intracellular calcium regulation is important. There is both  marked 
inwardly directed concentration gradient & electrical gradient. 
Endoplasmic reticulum is the major site for intracellular calcium store, 
which can be mobilised from which calcium can be mobilized  through 
specific channels. 
Calcium channels move calcium into the cells, these channels may 
be of ligand gated or voltage gated or stretch activated one. Intracellular 
calcium is increased by second messenger like IP3.Normal serum calcium 
level is 8.7-10.2 Mg/dl. 
Phosphorus is a common anion, distributed throughout the body, 
almost 80-85 % of the total body phosphorus is present in the skeleton, 
the remaining is in the form of organic phosphate compounds. intra 
cellular phosphorus is mainly sequestered in intracellular organelles, or 
incorporated into organic compounds like creatine phosphate, adenosine 
phosphate, and in RBCs as 2,3 bisphosphoglycerate. plasma phosphate is 
present in ionized, complexed and protein bound forms. phosphorus level 
is maintained by gastrointestinal tract, kidneys, parathyroid glands. 
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ELECTROLYTE ABNORMALITIES IN COPD 
COPD is a systemic disease, and serum electrolyte abnormalities 
are present in these patients. Retention of water and low serum sodium 
measurements are most common among these patients. In 1961, 
Campbell,Short108 pointed out that, in patients with COPD, carbon 
dioxide retention causes edeme. Though respiratory symptoms are 
common, other systemic effects(like metabolic disorders, electrolyte 
disorders, increased transaminases, increased renal parameters) are also 
common (Mohan et al,2006)109. Majority of them are treatable, but are 
frequently missed. so these metabolic derangements should be carefully 
looked which can modify mortality and morbidity these individuals.A 
study by Das et al 2010110, who measured the serum potassium and 
sodium in 64 individuals with acute exacerbation of COPD and compared 
the results with 20 healthy volunteers. They reported a significant 
decrease in serum Na & K levels in COPD patients. Also, A study by 
Teranzo et al 2012, 67 patients who got admitted in the hospital for 
exacerbation, low serum Na was seen in 11 patients. Reduced serum 
sodium with low chloride and potassium was found in 10 patients, and 
hypochloremia occurred in 7 patients. 
Beta 2-adrenoceptor agonists both inhaled like formetrol and 
salbutamol and oral like salbutamol or bumbetrol in addition to oral 
sustained released theophylline, are the main stay treatment in stable 
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COPD. All of these medications have been proved to cause some 
electrolyte disorders in patients with bronchial asthma and COPD (Yang 
et al, 1996)111. Development or worsening of hypoxia, hypercapnia and 
respiratory acidosis and right side heart failure with development of 
lower limb edema, renal insufficiency,diuretics use, SIADH (Syndrome 
of Inappropriate Antidiuretic Hormone Synthesis), malnourishment  and 
reduced food intake during acute exacerbations of COPD are common 
causes in these patients.Renin-angiotensin-aldosterone system activation 
and increased plasma arginine vasopressin (AVP) potentiate the 
electrolyte imbalance during acute exacerbation of COPD (Valli etal 
2004, Das etal 2010). 
A study comparing COPD patients with electrolyte disorders and 
those without any electrolyte imbalance on admission demonstrated there 
was a significant decrease in PH, PaO2 and oxygen saturation in patients 
with electrolyte disorders, with significant increase in PaCo2.These 
patients with electrolyte disorders, suffer from further deterioration in 
arterial blood gases than other group of patients without any electrolyte 
disorders. Frequent use of nebulized B2 agonists, i.v. aminophylline 
infusion and diuretics in patients with lower limb edema and systemic 
steroids are the main causes for deterioration of serum electrolytes. The 
effect of systemic steroids, diuretics, and nebulized b2 agonists on serum 
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electrolytes levels has proved in many studies on both COPD and 
asthmatic patients(Webb-Johnson and Andrews 1997, Yang et al 1996). 
Intravenous aminophylline therapy causes, hyponatraemia, 
hypocalcaemia and hypomagnesaemia in some patients by increasing the 
urinary loss of these electrolytes (Knutsen1994)112. 
COPD patients are susceptible to low serum sodium levels because 
of  carbon dioxide retention, heart failure or renal failure, diuretics use, 
SIADH, bronchodilators or steroids, malnutrition, acute exacerbations. 
Activation of RAS and increased levels of arginine vasopressin (AVP)  
cause hyponatremia (Bauer et al, 1965). Whatever be the cause 
hyponatremia  causes poor outcome these patients. It  causes central 
nervous system manifestation like seizure, coma, abnormalities in cardiac 
conduction, renal failure sometimes even death (Suri et al, 2009; Porcel 
et al, 2002). So all the patients with AECOPD are looked for 
hyponatremia and treatment should be started earlier.  
 Metabolic alkalosis, respiratory acidosis or long standing steroid 
therapy leads to low serum potassium in COPD patients (Saini et al, 
2008).Beta agonists like salbutamol also cause low serum potassium 
levels in COPD patients (1998, Yang et all).Increased mortality rate seen 
in COPD patients with low serum potassium with respiratory failure113. 
Cardiac arrhythmias or nerve conduction defects leads to increased 
mortality in these patients. 
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METHODOLOGY
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SETTING 
             This was a prevalence study done during the period of April 2016 
to September 2016 on 100 consecutive COPD patients in different stages 
of disease seen as inpatients in medical ward MADRAS MEDICAL 
COLLEGE (MMC), CHENNAI, TAMIL NADU, INDIA. 
All respondents were adults, aged more than 18 yrs. Informed 
consent was taken prior to inclusion in the study. 
 
PATIENTS 
Patients were selected on an in-patient basis in medical ward.The 
in-patients were those who were admitted to the medical wards of MMC 
during the aforementioned period. 
 
INCLUSION CRITERIA 
 
            Confirmed cases of chronic obstructive pulmonary disease 
 
 
METHOD OF COLLECTION OF DATA 
 
          All patients were interviewed and examined by the investigator. A 
Proforma, which is appended in the annexure, was used for the above 
purpose. 
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TESTS 
              Airflow limitation is assessed by spirometry. Serum electrolyte 
measurements were done by auto analyser. Other tests were done as per 
the needs of the patient.  
 
STATISTICAL METHODS 
Statistical analyses was performed with SPSS and summarized 
using mean and standard deviation (SD) for normal data and using 
median and interquartile range for non-normal data. 
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                                                   DEMOGRAPHY 
 
TABLE-1  AGE DISTRIBUTION 
 
AGE_GROUP FREQUENCY PERCENT 
 
 
 
 
 
 
30-40   YEARS 3 3.0 
41-50   YEARS 13 13.0 
51-60   YEARS 49 49.0 
61-70   YEARS 35 35.0 
Total 100 100.0 
 
 
 
 
                                 TABLE-2 AGE DISTRIBUTION 
 
Descriptive 
Statistics 
N Minimum Maximum Mean Std. Deviation 
AGE 100 35.00 70.00 57.7800 7.48410 
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AGE DISTRIBUTION 
  
                                                          CHART-1 
 
 
 
100 COPD PATIENTS WERE STUDIED. 
MINIMUM AGE WAS 35 YEARS AND THE MAXIMUM AGE WAS 70 YEARS. 
MEAN ±SD : 57.7800±7.48410 
53 
 
 
TABLE -3  GENDER DISTRIBUTION 
 
 
SEX Frequency Percent Valid Percent 
Cumulative 
Percent 
 
Male 78 78.0 78.0 78.0 
Female 22 22.0 22.0 100.0 
Total 100 100.0 100.0  
 
 
 
CHART-2 GENDER DISTRIBUTION 
 
 
 
78 %  OF THE SUBJECTS WERE MALES AND 22%  OF THE 
SUBJECTS WERE FEMALES 
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TABLE-4  CHEST X RAY FINDINGS DISTRIBUTION 
                                        
Chest X ray Frequency Percent 
 
H 82 82.0 
N 18 18.0 
Total 100 100.0 
 
 
CHART-3 CHEST X RAY FINDINGS DISTRIBUTION 
 
 
 
H- HYPERINFLATION 
                                                N- NORMAL                  
 
AMONG 100  COPD PATIENTS IN THE STUDY 82  HAD 
HYPERINFLATED LUNG,AND 18 HAD NORMAL CHEST X RAY 
FINDINGS. 
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TABLE-5   DISTRIBUTION ACCORDING TO SEVERITY  
OF COPD 
SEVERITY Frequency Percent 
 
Moderate COPD 72 72.0 
Severe  COPD 28 28.0 
Total 100 100.0 
 
 
 
CHART-4 DISTRIBUTION ACCORDING TO SEVERITY OF COPD 
 
78%
22%
SEVERITY OF COPD  
Moderate COPD
Severe COPD
 
78 % OF THE PATIENTS WERE IN MODERATE COPD,AND 22 % 
OF THEM WERE IN SEVERE COPD CATEGERY 
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TABLE-6   DISTRIBUTION ACCORDING TO FEV1 
 
 
Descriptive 
Statistics N 
Minimu
m 
Maximu
m 
Mean Std. Deviation 
FEV1__PREDIC
TED % 
100-
120 36.00 75.00 57.7400 10.68334 
             
 
RECORDED MINIMUM FEV1 WAS 33,MAXIMUM FEV1 WAS75. 
MEAN±SD:57.7400±10.68334 
 
TABLE-7   DISTRIBUTION OF SERUM SODIUM  LEVELS 
SERUM SODIUM Frequency Percent 
 
Hyponatremia 35 35.0 
NORMAL 65 65.0 
Total 100 100.0 
 
TABLE-8   DISTRIBUTION  OF  SERUM  SODIUM  LEVELS 
 
 N Minimum Maximum Mean Std. Deviation 
SERUM_SODIUM 100 123.00 145.00 137.0800 4.25139 
 
AMONG 100 PATIENTS IN THE STUDY 65 PATIENTS HAD 
NORMAL SERUM SODIUM LEVELS.35 PATIENTS HAD LOW 
SERUM SODIUM LEVELS(HYPONATREMIA). MINIMUM SERUM 
SODIUM LEVEL WAS 123 Meq/L,MAXIMUM SERUM SODIUM 
LEVEL WAS 145Meq/L.MEAN±SD LEVEL WAS 137.0800±4.25139. 
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TABLE-9  DISTRIBUTION OF SERUM  POTASSIUM  LEVELS 
 Frequency Percent 
Valid 
Hypokalemia 14 14.0 
NORMAL 86 86.0 
Total 100 100.0 
 
 
TABLE-10  DISTRIBUTION OF SERUM POTASSIUM 
LEVELS 
 
 N Minimu
m 
Maximu
m 
Mean Std. 
Deviation 
SERUM_POTASSI
UM 100 3.20 4.80 4.0100 .41621 
      
 
 CHART-6   DISTRIBUTION OF SERUM POTASSIUM LEVELS 
 
14%
86%
SERUM POTASSIUM
Hypokalemia
Normal
 
86% OF THE PATIENT HAD NORMAL SERUM POTASSIUM 
LEVELS,14% OF THE PATIENTS HAD LOW SERUM POTASSIUM 
LEVELS IN THE STUDY.MINIMUM SERUM POTASSIUM LEVEL 
WAS 3.2 Meq/L,MAXIMUM LEVEL WAS 4.8 Meq/L.MEAN±SD : 
4.0100±0.41621. 
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TABLE-11 DISTRIBUTION OF SERUM  CALCIUM 
 
 Frequency Percent 
Valid 
Hypocalcae
mia 9 9.0 
NORMAL 91 91.0 
Total 100 100.0 
 
TABLE-12  DISTRIBUTION OF SERUM CALCIUM 
 
 N Minimu
m 
Maximu
m 
Mean Std. Deviation 
SERUM_CALCIUM 100 8.30 10.00 9.1300 .38625 
      
 
                        CHART -7 DISTRIBUTION OF SERUM CALCIUM 
 
 
91 % HAD NORMAL SERUM CALCIUM,9% HAD LOW SERUM 
CALCIUM LEVELS IN THE STUDY.MAXIMUM SERUM 
CALCIUM LEVEL WAS 10 mg/dl,MINIMUM LEVEL WAS 8.3 
mg/dl.MEAN±SD :9.1300±0.38625. 
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TABLE-13    DISTRIBUTION OF SERUM PHOSPHOROUS 
 Frequency Percent 
 
Hypophosphatmia 2 2.0 
NORMAL 98 98.0 
Total 100 100.0 
 
TABLE-14   DISTRIBUTION OF SERUM PHOSPHOROUS 
LEVELS 
 
 
 N Minimu
m 
Maximu
m 
Mean Std. Deviation 
SERUM_PHOSPHORUS 100 2.30 4.20 3.6050 .40511 
      
  
CHART -8   DISTRIBUTION OF SERUM PHOSPHORUS LEVEL 
 
2%
98%
SERUM PHOSPHORUS
Hypophosphatemia
Normal
 
98 PATIENTS HAD NORMAL SERUM PHOSPHORUS LEVEL,2 
PATIENTS HAD LOW SERUM PHOSPHORUS LEVEL.MINIMUJM 
LEVEL WAS 2.3 mg/dl,MAXIMUM LEVEL WAS 4.2 mg/dl. 
MEAN±SD:3.06050±0.40511. 
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TABLE-15 CORRELATION BETWEEN COPD SEVERITY AND 
SERUM SODIUM LEVELS 
CROSSTAB 
 Na_group Total 
Hyponatremia NORMAL 
fev_ 
group 
Moderate  
COPD 
Count 14 58 72 
% within 
Na_group 40.0% 89.2% 72.0% 
Severe  COPD 
Count 21 7 28 
% within 
Na_group 60.0% 10.8% 28.0% 
Total 
Count 35 65 100 
% within 
Na_group 100.0% 100.0% 100.0% 
Chi-Square=27.350* p<0.001 
 
CHART-9 CORRELATION BETWEEN COPD SEVERITY AND 
SERUM SODIUM LEVELS 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Hyponatremia Normal
40%
89%
60%
11%
Severe COPD
Moderate COPD
 
IN THIS STUDY OF 100 COPD PATIENTS,NORMAL SERUM 
SODIUM LEVEL WAS PRESENT IN 65 PATIETS.HYPONATREMIA 
WAS PRESENT IN 35 PATIENTS,AMONG THEM 40 %  WERE 
MODERATE COPD PATIENTS AND 60 % WERE SEVERE COPD 
PATIENTS.
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TABLE-16 CORRELATION BETWEEN COPD SEVERITY AND 
SERUM POTASSIUM LEVEL 
CROSSTAB 
 potassium_group Total 
HYPO-
KALEMIA 
NORMAL 
fev_ 
group 
Moderate  
COPD 
Count 3 69 72 
% within potassium_group 21.4% 80.2% 72.0% 
Severe  
COPD 
Count 11 17 28 
% within potassium_group 78.6% 19.8% 28.0% 
 
Total 
Count 14 86 100 
% within potassium_group 100.0% 100.0% 100.0% 
Chi-Square=20.651* p<0.001  
 
78.6 % of the patients with hypokalemia severe COPD. 
 
CHART-10 CORRELATION BETWEEN COPD SEVERITY AND 
SERUM POTASSIUM LEVEL 
  
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Hypokalemia Normal
21%
80%
79%
20%
Severe COPD
Moderate COPD
NORMAL SERUM POTASSIUM LEVEL WAS PRESENT IN 86 
PATIENT.HYPOKALEMIA WAS PRESENT IN 14 
PATIENTS.AMONG THEM  21 %  WERE MODERATE COPD AND 
79 % WERE SEVERE COPD PATIENTS. 
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TABLE-17 CORRELATION BETWEEN COPD SEVERITY AND 
SERUM CALCIUM LEVEL 
CROSSTAB 
 calcium_group Total 
HYPO-
CALCEMIA 
NORMAL 
fev_ 
group 
Moderate  
COPD 
Count 7 65 72 
% within calcium_group 77.8% 71.4% 72.0% 
Severe  
COPD 
Count 2 26 28 
% within calcium_group 22.2% 28.6% 28.0% 
Total Count 9 91 100 % within calcium_group 100.0% 100.0% 100.0% 
Chi-Square=0.164  p=0.686 
 
CHART-11 CORRELATION BETWEEN COPD SEVERITY AND 
SERUM CALCIUM LEVEL 
 
NORMAL CALCIUM LEVEL WAS PRESENT  91 OUT OF 100 
PATIENTS IN THE STUDY.HYPOCALCEMIA WAS PRESENT IN 9 
PATIENTS,AMONG THEM 78 % OF THE PATIENTS HAD 
MODERATE COPD AND 22 % OF THE PATIENTS  HAD SEVERE 
COPD. 
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TABLE-18 CORRELATION BETWEEN COPD SEVERITY AND 
SERUM PHOSPHORUS LEVEL 
CROSSTAB 
 phosphorus_group 
Total HYPO- 
PHOSPHATEMIA 
NORMAL 
fev_ 
group 
Moderate  
COPD 
Count 2 70 72 
% within 
phosphorus_group 100.0% 71.4% 72.0% 
Severe  
COPD 
Count 0 28 28 
% within 
phosphorus_group 0.0% 28.6% 28.0% 
 
Total 
Count 2 98 100 
% within 
phosphorus_group 100.0% 100.0% 100.0% 
Chi-Square=0.794   p=0.373  
 
CHART-12  CORRELATION BETWEEN COPD SEVERITY AND 
SERUM PHOSPHORUS LEVEL 
98 OUT OF 100 PATIENTS IN THE STUDY HAD NORMAL SERUM 
PHOSPHORUS LEVEL.2  OUT OF 100 HAD 
HYPOPHOSPHATEMIA,AND THAT WAS PRESENT IN 
MODERATE COPD GROUP.  
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TABLE-19 AGE GROUP AND SEVERITY OF COPD 
DISTRIBUTION 
 
CROSSTAB 
 age_group Total 
30-40 41-50 51-60 61-70 
fev_ 
group 
Moderate  
COPD 
Count 3 12 32 25 72 
% within 
age_group 100.0% 92.3% 65.3% 71.4% 72.0% 
Severe  
COPD 
Count 0 1 17 10 28 
% within 
age_group 0.0% 7.7% 34.7% 28.6% 28.0% 
Total 
Count 3 13 49 35 100 
% within 
age_group 100.0% 100.0% 100.0% 100.0% 100.0% 
Chi-Square=0.794 * p=0.178 
 
 
CHART-13 AGE GROUP AND SEVERITY DISTRIBUTION 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
30-40 41-50 51-60 61-70
100%
92%
65%
71%
0%
8%
35%
29%
Severe COPD
Moderate COPD
 
MOST OF THE SUBJECTS  WERE 51-60 YEARS  AGE 
GROUP,FOLLOWED BY 61-70 YEARS AGE GROUP.MOST OF 
THEM WERE IN MODERATE COPD GROUP. 
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TABLE-20 SEVERITY OF COPD AND SEX DISTRIBUTION 
                                                           CROSSTAB 
 SEX Total 
Male Female 
fev_group 
Moderate 
COPD 
Count 54 18 72 
% within SEX 69.2% 81.8% 72.0% 
Severe 
COPD 
Count 24 4 28 
% within SEX 30.8% 18.2% 28.0% 
Total Count 78 22 100 % within SEX 100.0% 100.0% 100.0% 
Chi-Square=1.349  p=0.246  
 
CHART-14 SEVERITY OF COPD AND SEX DISTRIBUTION 
 
69 % OF THE MALES HAD MODERATE COPD,82 % OF THE 
FEMALES HAD  MODERATE COPD.
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TABLE-21 DISTRIBUTION OF HYPONATREMIA IN 
DIFFERENT AGE GROUPS 
CROSSTAB 
 Na_group Total 
HYPONATREMIA NORMAL 
age_ 
group 
30-40 Count 0 3 3 % within Na_group 0.0% 4.6% 3.0% 
41-50 Count 7 6 13 % within Na_group 20.0% 9.2% 13.0% 
51-60 Count 16 33 49 % within Na_group 45.7% 50.8% 49.0% 
61-70 Count 12 23 35 % within Na_group 34.3% 35.4% 35.0% 
Total Count 35 65 100 % within Na_group 100.0% 100.0% 100.0% 
Chi-Square=3.771   p=0.2487 
 
CHART-15  DISTRIBUTION OF HYPONATREMIA IN 
DIFFERENT AGE GROUPS 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
HYPONATREMIA Normal
0% 5%
20% 9%
46%
51%
34% 35%
61-70
51-60
41-50
30-40
MOST OF THE HYPONATREMIC INDIVIDUALS IN THE STUDY 
WERE IN  51-60 YEARS AGE GROUP,FOLLOWED BY 61-70 
YEARS AGE GROUP. 
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TABLE-22 HYPOKALEMIA AND AGE DISTRIBUTION 
                                                                           CROSSTAB 
 potassium_group Total 
HYPOKALEMIA NORMAL 
age_ 
group 
30-40 
Count 0 3 3 
% within 
potassium_group 0.0% 3.5% 3.0% 
41-50 
Count 1 12 13 
% within 
potassium_group 7.1% 14.0% 13.0% 
51-60 
Count 6 43 49 
% within 
potassium_group 42.9% 50.0% 49.0% 
61-70 
Count 7 28 35 
% within 
potassium_group 50.0% 32.6% 35.0% 
Total 
Count 14 86 100 
% within 
potassium_group 100.0% 100.0% 100.0% 
Chi-Square=2.090   p=0.554 
 
             CHART-16 HYPOKALEMIA AND AGE DISTRIBUTION 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
HYPOKALEMI Normal
0% 4%
7%
14%
43%
50%
50%
33%
61-70
51-60
41-50
30-40
 
 
43 % OF HYPOKALEMIC PATIENTS  IN THE STUDY WERE IN 51-
60 YEARS  AGE GROUP. 
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TABLE-23 HYPOCALCEMIA AND AGE DISTRIBUTION 
CROSSTAB 
 calcium_group Total 
HYPO- 
CALCAEMIA 
NORMAL 
age_ 
group 
30-40 Count 0 3 3 % within calcium_group 0.0% 3.3% 3.0% 
41-50 Count 3 10 13 % within calcium_group 33.3% 11.0% 13.0% 
51-60 Count 2 47 49 % within calcium_group 22.2% 51.6% 49.0% 
61-70 Count 4 31 35 % within calcium_group 44.4% 34.1% 35.0% 
Total Count 9 91 100 % within calcium_group 100.0% 100.0% 100.0% 
Chi-Square=5.141   p=0.162 
 
CHART-17 HYPOCALCEMIA AND AGE DISTRIBUTION 
 
    
9 OUT OF 100 PATIENTS IN THE STUDY HAD 
HYPOCALCEMIA,MOST OF THEM     WERE IN THE AGE GROUP 
OF 61-70. 
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TABLE-24 HYPOPHOSPHATEMIA AND AGE DISTRIBUTION 
CROSSTAB 
 phosphorus_group Total 
HYPO- 
PHOSPHATEMIA 
NORMAL 
age_ 
group 
30-40 
Count 0 3 3 
% within 
phosphorus_group 0.0% 3.1% 3.0% 
41-50 
Count 1 12 13 
% within 
phosphorus_group 50.0% 12.2% 13.0% 
51-60 
Count 0 49 49 
% within 
phosphorus_group 0.0% 50.0% 49.0% 
61-70 
Count 1 34 35 
% within 
phosphorus_group 50.0% 34.7% 35.0% 
Total 
Count 2 98 100 
% within 
phosphorus_group 100.0% 100.0% 100.0% 
Chi-Square=3.342   p=0.342 
 
CHART-18  HYPOPHOSPHATEMIA AND AGE DISTRIBUTION 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
HYPOPHOSPHATEMIA Normal
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50%
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30-40
 
2 OUT OF 100 PATIENTS HAD HYPOPHOSPHATEMIA,1 FROM 
61-70 AGE GROUP, 1FROM 41-50 AGE GROUP. 
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TABLE-25 CORRELATION BETWEEN COMBINED 
HYPONATREMIA & HYPOKALEMIA AND COPD SEVERITY 
 
 
 
Total NORMAL LOW SODIUM AND LOW POTASSIUM 
fev_ 
group 
Moderat
e 
COPD 
Count 71 1 72 
%) 80.7% 8.3% 72.0% 
Severe 
COPD 
Count 17 11 28 
% 19.3% 91.7% 28.0% 
Total Count 88 12 100 % 100.0% 100.0% 100.0% 
Chi-Square=27.418*   p<0.001 
 
 
CHART-19 CORRELATION BETWEEN COMBINED 
HYPONATREMIA & HYPOKALEMIA AND COPD SEVERITY 
 
12 PATIENTS HAD CORRELATION BETWEEN COMBINED 
HYPONATREMIA & HYPOKALEMIA.MOST OF THEM HAD 
SEVERE COPD. 
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TABLE 26-SERUM SODIUM  IN MALES AND FEMALES 
 
Crosstab 
 Na_group Total 
HYPO- 
NATREMIA 
NORMAL 
SEX 
Male 
Count 28 50 78 
% within 
Na_group 80.0% 76.9% 78.0% 
Female 
Count 7 15 22 
% within 
Na_group 20.0% 23.1% 22.0% 
Total 
Count 35 65 100 
% within Na_ 
group 100.0% 100.0% 100.0% 
Chi-Square =0.126   p=0.723  
 
80 % of Hyponatremia patients were males. 
 
TABLE 27-SERUM POTASSIUM IN MALES AND FEMALES 
 
Crosstab 
 potassium_group 
Total HYPO-
KALEMIA 
NORMAL 
SEX 
Male Count 11 67 78 % within potassium_group 78.6% 77.9% 78.0% 
Female Count 3 19 22 % within potassium_group 21.4% 22.1% 22.0% 
Total Count 14 86 100 % within potassium_group 100.0% 100.0% 100.0% 
Chi-Square =0.003       p = 0.956 
 
78.6 % of the hypokalemia patients were males. 
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TABLE 28-SERUM CALCIUM IN MALES AND FEMALES 
 
Crosstab 
 
calcium_group 
Total HYPO-
CALCAEMIA NORMAL 
SEX 
Male Count 2 76 78 % within calcium_group 22.2% 83.5% 78.0% 
Female Count 7 15 22 % within calcium_group 77.8% 16.5% 22.0% 
Total Count 9 91 100 % within calcium_group 100.0% 100.0% 100.0% 
Chi-Square =17.931 * p <0.001  
 
77.8 % of the hypocalcemia patients were females. 
 
 
TABLE 29-SERUM PHOSPHORUS  IN MALES AND FEMALES 
Crosstab 
 
phosphorus_group 
Total HYPO-
PHOSPHATEMIA NORMAL 
SEX 
Male 
Count 2 76 78 
% within 
phosphorus_group 100.0% 77.6% 78.0% 
Female 
Count 0 22 22 
% within 
phosphorus_group 0.0% 22.4% 22.0% 
Total 
Count 2 98 100 
% within 
phosphorus_group 100.0% 100.0% 100.0% 
 
Chi-Square =0.576   p =0.448  
 
2 out of 2 patients with hypophosphatemia were males. 
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DISCUSSION 
 
In this study 100 COPD patients who were admitted in the medical 
wards were included.78 of them were male patients,22 of them were 
female patients. Those patients with diabetic ketoacidosis, chronic kidney 
diseases, chronic liver disease, asthmatic individuals, those who are on 
diuretics therapy were excluded from the study. 
 
DEMOGRAPHY 
                Minimum age of the subject was 35 yrs, and the maximum age 
was 70 yrs with Mean±SD:57.7800±7.48410.Majority of the patients 
were in 51-60 years age group, followed by 61-70 yrs age group. There 
were 78 male patients,22 female patients in the study. Majority of our 
study population were from Tamilnadu and adjoining parts of Andhra 
Pradesh. Madras Medical College is major referral center for patients 
from these areas. patients from Tamilnadu  and part of Andhra Pradesh 
utilize the services of this hospital and the study can be considered as 
done in a south Indian population. 
 
FEATURES OF PATIENTS WITH COPD 
Among the patients studied,72 out of 100 patients were moderate 
COPD group,28 out of 100 were severe COPD group, with respect to 
FEV1 %.minimum FEV1 predicted was 36,maximum FEV1 predicted 
was 75 (Mean ±SD:57.7400±10.68334).Guidelines of the global 
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initiative for chronic obstructive lung disease were followed to interpret 
FEV1.GOLD interpretes COPD according to mild, moderate, severe, 
very severe airflow limitation..Among 100 patients studied 82 of them 
had hyperinflatted lung,18 had normal findings on chest X ray. All the 
patients were in moderate and severe COPD group, this probably because 
our study was done in those patients who got admitted at medical wards. 
mild COPD patients might have treated as outpatient and very severe 
degree of patients treated at intensive care units. Among our patients,35 
had low serum sodium,14 had low serum potassium,9 patients had low 
serum calcium,2 patients had low serum phosphorous. 
 
SERUM SODIUM LEVEL 
In our study, among 100 patients, lowest serum sodium level 
recorded was 123 Meq /L,highest serum sodium level recorded was 145 
Meq/L.65 had normal sodium levels,35 had low serum sodium levels 
(hyponatremia).80%(28)of them were males,20% (7 )of them were 
females. Among low serum sodium level patients 40%(14) of the patients 
were moderate COPD,60% (21) had severe COPD.45.7%(16) of the 
hyponatremic patients were 51-60 years of age,34.3%(12) were in the age 
group of 61-70 age group,20%(7) were 41-50 yrs age group. 
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SERUM POTASSIUM 
 In the study of 100 patients, lowest potassium level recorded was 
3.2 Meq/L, highest potassium level recorded was 4.8 Meq/L.14 out of 
100 patients had low serum potassium(hypokalemia),78.6% (11) of them 
were males,21.4% (3) of them were females.50% (7) of them were in the 
age group of 61-70, 42.9% (6) of them were in 51-60 years of age,7.1% 
(1) was in 41-50 years age group.78.6% (11) were severe COPD 
patients,21.4% ( 3) of them were moderate COPD patients. 
 
 
SERUM CALCIUM 
 In our study population,91 out of 100 had normal serum calcium 
levels,9 out of 100 had low serum calcium levels, minimum serum 
calcium recorded was 8.3 mg/dl, maximum level recorded was 10 mg/dl, 
Mean ±SD:9.1300±0.38625. 77.8% (7) were moderate COPD,22,2%(2) 
were in severe COPD group.44.4%(4) patients were in 61-70 years of age 
group,33.3%(3) were  in 41-50 years of age group,22.2%(2) were in 51-
60 years of age group.77.8%(7) of the hypocalcemic patients were 
females,22.2(2) of them were male patients. 
 
77 
 
PHOSPHORUS 
In our study, 98 out of 100 patients had normal serum phosphorus 
level,2 had low serum phosphorus (hypophosphatemia). lowest serum 
phosphorus level recorded was 2.3 mg/dl, maximum level recorded was 
4.2 mg/dl,Mean±SD:3.6050±0.40511.Hypophosphatemia was seen only 
in two patients, both of them had moderate COPD. one from 41-50,and 
the other one from 61-70 years of age group and both them were male 
patients. 
 
COMBINED LOW SERUM SODIUM AND LOW SERUM 
POTASSIUM 
Out of 100 patients in our study,12 of them had combined low 
serum sodium (hyponatremia) and low serum potassium (hypokalemia). 
This showed that  there was a significant and positive interpretation of 
presence  combined hyponatremia and hypokalmia.Chi-square=27.418, 
p<0.001.Among combined hyponatremia and hypokalemia 91.7% (11) 
had sever COPD,8.3% (1) had moderate COPD.This association can be 
explained by the fact that the patients might be on for combined drug 
therapy like beta agonists and corticosteroids, and associated with 
hypercapnea.  
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Limitations of the study 
1. The study has a few limitations that needs to be mentioned. 
2. The number of cases studied were 100.This number is much 
smaller when compared to the prevalence of the disease. 
3. There is selection bias. All of the patients were selected from 
medical wards, so the patients treated as outpatient were not 
included. 
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CONCLUSION 
 
In this study 100 COPD patients who were admitted in the medical 
wards were included.78 of them were male patients, 22 of them were 
female patients. Those patients with diabetic ketoacidosis, chronic kidney 
diseases, chronic liver disease, asthmatic individuals, those who are on 
diuretics therapy were excluded from the study. 
 
Patients mean age was 57.7800,and the disease was seen mostly in 
51-60 yrs of age, then followed by 61-70 years age group. most of the 
subjects were males. Most of the patients had moderate COPD, according 
to airflow limitation by spirometry. most of the patients had hyperinflated 
lung finding on chest x ray. 
 
Low serum sodium level (hyponatremia) was present in a subset of 
patients, mean serum sodium level  recorded was137.0800.hyponatremia 
was more commonly present in severe COPD patients, and was noted 
more in male patients. 
 
               Low potassium level (hypokalemia) was present in some 
patients. Mean serum potassium level was 4.0100.Hypokalemia was 
more commonly present in severe COPD patients. Hypokalemia was 
most commonly present in 61-70 years of age group patients, and it was 
more common in males. 
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Low serum calcium (hypocalcemia) was present in some patients. 
Mean serum calcium was 9.1300. Hypocalcemia was present more 
commonly in moderate COPD patients, and it was more common in  
61-70 years of age group patients. Hypocalcemia was more common in 
females than males. 
 
                Low serum phosphorus level was present only in two patients, 
both of them were male, among them one had moderate and another one 
had severe COPD. 
 
Combined Hyponatremia and Hypokalemia was present in some 
patients, most of them had severe COPD. 
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ANNEXURE  
PREVALENCE OF ELECTROLYTE ABNORMALITIES IN 
CHRONIC BSTRUCTIVE PULMONARY DISEASE 
  PROFORMA 
Name:      Age/Sex: 
Address:      Occupation: 
SYMPTOMS: 
Breathlessness  
Chronic Cough and expectoration  
wheezing  
Chest tightness  
Easy fatiguability  
 
PAST HISTORY: 
CAD  
CKD  
CLD  
 
PERSONAL HISTORY: 
SMOKING 
ALCOHOL 
GENERAL EXAMINATION: 
Pallor 
Icterus 
Cyanosis 
Clubbing 
Pedal edema 
Lymphadenopathy 
BMI: 
VITAL SIGNS: 
        PR- 
       BP- 
        RR- 
 SPO2 
 Temp- 
 
SYSTEMIC  EXAMINATION: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
  
INVESTIGATIONS: 
COMPLETE  HEMOGRAM: 
 Hemoglobin: 
 MCV: 
 MCH: 
 MCHC: 
 Hematocrit: 
 ESR: 
BLOOD UREA                  : 
SERUM CREATININE     : 
SERUM SODIUM             : 
SERUM POTASSIUM      : 
SERUM CALCIUM          : 
SERUM PHOSPHORUS  : 
CHEST X RAY                 : 
SPIROMETRY                  : 
 
 
  
LIST OF ABBREVIATIONS USED 
 
AECOPD  ACURE EXACERBATION OF COPD 
ATS   AMERICAN THORACIC SOCIETY 
AVP   ARGININE VASIPRESSIN 
BUN   BLOOD UREA NITROGEN 
Ca   CALCIUM 
C-AMP  CYCLIC ADENOSINE MONOPHOSPHATE 
C-GMP  CYCLIC GUANOSINE MONOPHOSPHATE 
CXCR  C-X-C CHEMOKINE RECEPTOR 
DALY  DISABILITY ADJUSTED LIFE YEARS 
ERS   EUROPIAN RESPIRATORY SOCIETY 
ETS   ENVIRONMENTAL TOBACCO SMOKE 
FEV   FORCED EXPIRATORY VOLUME 
FVC   FORCED VITAL CAPACITY 
GOLD  GLOBAL INITIATIVE FOR COPD 
HIV   HUMAN IMMUNODEFICIENCY VIRUS 
ICS   INHALED CORTICOSTERODS 
IL   INTERLEUKIN 
IPPV   INVASIVE POSITIVE PRESSURE  
   VENTILLATION 
IP3   INOSITOL TRIPHOSPHATE 
K   POTASSIUM  
LABA  LONG ACTING BETA AGONIST 
LAMA  LONG ACTING ANTIMUSCARANIC AGENT 
MMP  MATRIX METALLOPROTEINASE 
NIPPV  NON INVASIVE POSITIVE PRESSURE  
   VENTILLATION 
Na                   SODIUM 
PDE                PHOSPHODIESTERASE 
PO4                 PHOSPHATE 
SABA             SHORT ACTING BETA AGONIST 
SAMA            SHORT ACTING ANTIMUSCARANIC AGENT 
TB                  TUBERCULOSIS 
 
  
INFORMATION SHEET 
            We are conducting a study on “PREVALENCE OF 
ELECTROLYTE ABNORMALITIES IN CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE” among patients attending 
Rajiv Gandhi Government General Hospital, Chennai and for that your 
specimen may be valuable to us. 
           The purpose of this study is to to estimate Serum electrolytes in 
patients with chronic obstructive pulmonary disease and to measure 
electrolyte abnormalities in them. 
We are selecting certain cases and if you are found eligible, we 
may be using your blood samples to do certain tests which in any way do 
not affect your final report or management. 
The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment. 
 
Signature of Investigator    Signature of Participant 
 
 
Date:  
Place:
PATIENT CONSENT FORM 
Study Detail : 
 “PREVALENCE OF ELECTROLYTE ABNORMALITIES 
IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification Number :  
Patient may check (√) these boxes 
 I confirm that I have understood the purpose of procedure for the above study. I have 
the opportunity to ask question and all my questions and doubts have been answered to 
my complete satisfaction. 
❏ 
 I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
❏ 
 I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to 
look at my health records, both in respect of current study and any further research that 
may be conducted in relation to it, even if I withdraw from the study I agree to this 
access. However, I understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I agree not to 
restrict the use of any data or results that arise from this study. 
❏ 
 I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperate with the study team and to immediately inform the 
study staff if I suffer from any deterioration in my health or well being or any 
unexpected or unusual symptoms. 
❏ 
 I hereby consent to participate in this study. ❏ 
 I hereby give permission to undergo detailed clinical examination and blood 
investigations as required. 
❏ 
 
Signature/thumb impression     Signature of Investigator 
 
Patient’s Name and Address:                                           Study Investigator’s Name: 
                                                                                          Dr.K.RAVI 
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